Status:
COMPLETED
Evaluate the Safety and Anti-Hypertensive Efficacy of Hyzaar(R) In Patients With Mild To Moderate Essential Hypertension (0954A-323)
Lead Sponsor:
Organon and Co
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Evaluate the safety and anti-hypertensive efficacy of hyzaar(R) in patients with mild to moderate essential hypertension.
Eligibility Criteria
Inclusion
- Patient is either receiving high blood pressure monotherapy or no treatment
- Patient will have reached the legal age by the time enter the study
- Patients diagnosed with mild to moderate essential high blood pressure or high blood pressure with other conditions such as diabetes or cardiovascular diseases and are taking high blood pressure medication (exclude diuretic), but did not meet treatment goal
Exclusion
- Patient with high levels of uric acid in the blood who has received medications for uric acid in the urine within 3 months prior to enrollment
- Patients who are hypersensitive to any component of the study medication
- Patients who are hypersensitive to other sulfonamide-derived drugs
- Patients with anuria (hyzaar(R) is not recommended for patients with hepatic impairment or severe renal impairment, creatinine clearance \</= 30 ml/min)
- Unstable diabetes (hba1c \> 8%), or a change in diabetes medication during study treatment. patients with stable diabetes may enter the study.
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 19 2006
Estimated Enrollment :
62 Patients enrolled
Trial Details
Trial ID
NCT00400218
Start Date
September 1 2005
End Date
July 19 2006
Last Update
August 15 2024
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.